pioglitazone and Idiopathic Parkinson Disease studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

Excerpt	Relevance	Reference
"The pharmacologic effects of pioglitazone on the incidence of Parkinson disease (PD) are not clear."	8.02	Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes mellitus. ( Chang, YH; Lin, KD; Wu, WJ; Yen, SJ, 2021)
"Pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, is known to have anti-inflammatory and anti-oxidant effects on the brain, and its clinical potential in the treatment of cognitive impairment in diseases such as Alzheimer's disease (AD) and Parkinson disease (PD) is currently being explored."	5.22	Protective Effects of Pioglitazone on Cognitive Impairment and the Underlying Mechanisms: A Review of Literature. ( Aldubayan, M; Alhowail, A; Alsaud, M; Alsikhan, R; Rabbani, SI, 2022)
" We analyzed peripheral biomarkers, including leukocyte PGC-1α and target gene expression, plasma interleukin 6 (IL-6) as a marker of inflammation, and urine 8-hydroxydeoxyguanosine (8OHdG) as a marker of oxidative DNA damage."	5.20	Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects. ( Baker, L; Clark-Matott, J; Dunlop, SR; Elm, J; Emborg, M; Graebner, AK; Kamp, C; Morgan, JC; Ravina, B; Ross, GW; Sharma, S; Simon, DK; Simuni, T, 2015)
"The pharmacologic effects of pioglitazone on the incidence of Parkinson disease (PD) are not clear."	4.02	Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes mellitus. ( Chang, YH; Lin, KD; Wu, WJ; Yen, SJ, 2021)
" Differentiated SH-SY5Y neuroblastoma cells were exposed to the PD relevant mitochondrial complex 1 inhibitor 1-methyl-4-phenylpyridinium iodide (MPP+)."	3.83	Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis. ( Carroll, CB; Eastwood, J; Hanemann, CO; McCorry, K; Zajicek, JP; Zeissler, ML, 2016)
"Current treatment of Parkinson's disease (PD) is limited to symptomatic dopaminergic therapy, while no interventions have been shown to slow down disease progression."	2.52	Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease. ( Carta, AR; Simuni, T, 2015)

Research

Studies (15)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change in Ambulatory Capacity From Baseline to 44 Weeks

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	11 (73.33)	24.3611
2020's	4 (26.67)	2.80

Authors	Studies
Rojas, RJ	1
Edmondson, DE	1
Almos, T	1
Scott, R	1
Massari, ME	1
Alhowail, A	1
Alsikhan, R	1
Alsaud, M	1
Aldubayan, M	1
Rabbani, SI	1
Zamanian, MY	1
Terefe, EM	1
Taheri, N	1
Kujawska, M	1
Tork, YJ	1
Abdelbasset, WK	1
Shoukat, S	1
Opulencia, MJC	1
Heidari, M	1
Alesaeidi, S	1
Chen, L	1
Tao, Y	1
Li, J	1
Kang, M	1
Chang, YH	2
Yen, SJ	1
Wu, WJ	1
Lin, KD	1
Wu, HF	1
Kao, LT	1
Shih, JH	1
Kao, HH	1
Chou, YC	1
Li, IH	1
Kao, S	1
Machado, MMF	1
Bassani, TB	1
Cóppola-Segovia, V	1
Moura, ELR	1
Zanata, SM	1
Andreatini, R	1
Vital, MABF	1
Carta, AR	2
Simuni, T	2
Simon, DK	1
Elm, J	1
Clark-Matott, J	1
Graebner, AK	1
Baker, L	1
Dunlop, SR	1
Emborg, M	1
Kamp, C	1
Morgan, JC	1
Ross, GW	1
Sharma, S	1
Ravina, B	1
Pinto, M	1
Nissanka, N	1
Peralta, S	1
Brambilla, R	1
Diaz, F	1
Moraes, CT	1
Zeissler, ML	1
Eastwood, J	1
McCorry, K	1
Hanemann, CO	1
Zajicek, JP	1
Carroll, CB	1
Welling, LC	1
Welling, MS	1
Teixeira, MJ	1
Figueiredo, EG	1
He, B	1
Tang, J	1
Ding, Y	1
Wang, H	1
Sun, Y	1
Shin, JH	1
Chen, B	1
Moorthy, G	1
Qiu, J	1
Desai, P	1
Wild, DJ	1
Pisanu, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Multi-Center, Double-Blind, Placebo-Controlled Phase II Study of Pioglitazone in Early Parkinson's Disease[NCT01280123]	Phase 2	210 participants (Actual)	Interventional	2011-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"This is the sum of the 5 UPDRS questions regarding ambulatory capacity: falling, freezing, walking, gait, postural stability.~Ambulatory Capacity is calculated as the sum of items 13-15, 29, 30 of the Unified Parkinson's Disease Rating Scale (UPDRS). It ranges from 0-20. Higher scores are worse. Change is 44 weeks - baseline." (NCT01280123)
Timeframe: 44 weeks

Change in Parkinson's Disease Questionnaire (PDQ-39) From Baseline to 44 Weeks

Intervention	units on a scale (Mean)
15 mg Pioglitazone	0.39
45 mg Pioglitazone	0.38
Matching Placebo	0.4

"The Parkinson's Disease Questionnaire (PDQ-39) is a short, 39 item measure of quality of life in subjects with Parkinson's disease. The questionnaire covers 8 aspects of quality of life: mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication and bodily discomfort.~The total score ranges from 0 (never have difficulty) to 100 (always have difficulty). Lower scores reflect better quality of life." (NCT01280123)
Timeframe: 44 weeks

Change in Schwab and England Scale From Baseline to 44 Weeks

Intervention	units on a scale (Mean)
15 mg Pioglitazone	2.03
45 mg Pioglitazone	2.08
Matching Placebo	0.08

The modified Schwab and England Activities of Daily Living is a single question ranging from 0-100% with anchors for each 10% interval. Higher scores are better (100% completely independent- 0% vegetative). (NCT01280123)
Timeframe: 44 weeks

Change in the 15-item Geriatric Depression Scale (GDS-15)From Baseline to 44 Weeks

Intervention	units on a scale (Mean)
15 mg Pioglitazone	-2.12
45 mg Pioglitazone	-2.52
Matching Placebo	-1.84

The Geriatric Depression Scale - 15 is a short 15 yes or no question instrument for assessing depression in the elderly. It has been found to be particularly useful in assessing depression in Parkinson's Disease. A score of 0 to 5 is normal. A score greater than 5 suggests depression. (NCT01280123)
Timeframe: 44 weeks

Change in the Mattis Dementia Rating Scale (DRS-2)From Baseline to 44 Weeks

Intervention	units on a scale (Mean)
15 mg Pioglitazone	0.13
45 mg Pioglitazone	0.38
Matching Placebo	0.18

The Mattis dementia rating scale is a psychometric instrument designed to assess the extent and nature of dementia. Mattis Dementia Rating scale (DRS-2) raw score is the sum of 5 raw sub-scores (attention has possible 37 points, initiation/perseveration has possible 37 points, construction has possible 6 points, conceptualization has possible 39 points, memory has possible 25 points). Total range is 0-144. Higher scores are better. (NCT01280123)
Timeframe: 44 weeks

Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline to 44 Weeks

Intervention	units on a scale (Mean)
15 mg Pioglitazone	1.16
45 mg Pioglitazone	2.11
Matching Placebo	3.16

"Change in total UPDRS score from baseline to 44 weeks (in subjects treated with rasagiline 1 mg/day or selegiline 10 mg/day).~The Total UPDRS is the sum of parts I, II, and III. The possible range of the total UPDRS is from 0-176. Higher values indicate worse outcomes.~The change is 44 weeks - baseline." (NCT01280123)
Timeframe: 44 weeks

Article	Year
Protective Effects of Pioglitazone on Cognitive Impairment and the Underlying Mechanisms: A Review of Literature. Drug design, development and therapy, 2022, Volume: 16 Topics: Alzheimer Disease; Antioxidants; Cognitive Dysfunction; Humans; Hypoglycemic Agents; Parkinson Disea	2022
Neuroprotective and Anti-Inflammatory Effects of Pioglitazone on Parkinson's Disease: A Comprehensive Narrative Review of Clinical and Experimental Findings. CNS & neurological disorders drug targets, 2023, Volume: 22, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Neuroprotective Agents; Parkinson Disease; Pioglita	2023
Pioglitazone use is associated with reduced risk of Parkinson's disease in patients with diabetes: A systematic review and meta-analysis. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2022, Volume: 106 Topics: Diabetes Mellitus; Humans; Odds Ratio; Parkinson Disease; Pioglitazone; Risk	2022
Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease. Expert opinion on investigational drugs, 2015, Volume: 24, Issue:2 Topics: Animals; Antiparkinson Agents; Disease Progression; Dopamine; Drug Evaluation, Preclinical; Humans;	2015
Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease? Neurotoxicity research, 2013, Volume: 23, Issue:2 Topics: Animals; Antiparkinson Agents; Encephalitis; Humans; Microglia; Parkinson Disease; Pioglitazone; PPA	2013

Article	Year
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. The Lancet. Neurology, 2015, Volume: 14, Issue:8 Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indans; Male; Medical Futility	2015
Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects. Journal of Parkinson's disease, 2015, Volume: 5, Issue:4 Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Biomarkers; Deoxyguanosine; Disease Progression; Female; Gene Exp	2015

Article	Year
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques. Bioorganic & medicinal chemistry, 2015, Feb-15, Volume: 23, Issue:4 Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Small Molecule Libraries	2015
Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes mellitus. European journal of neurology, 2021, Volume: 28, Issue:2 Topics: Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Parkinson Dise	2021
Pioglitazone use and Parkinson's disease: a retrospective cohort study in Taiwan. BMJ open, 2018, 08-29, Volume: 8, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Incidence; M	2018
PPAR-γ agonist pioglitazone reduces microglial proliferation and NF-κB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson's disease. Pharmacological reports : PR, 2019, Volume: 71, Issue:4 Topics: Animals; Disease Models, Animal; Male; Microglia; Motor Activity; Neuroprotective Agents; NF-kappa B	2019
Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation. Molecular neurodegeneration, 2016, Apr-02, Volume: 11 Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Inflammation; Mese	2016
Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis. Oncotarget, 2016, Jul-19, Volume: 7, Issue:29 Topics: 1-Methyl-4-phenylpyridinium; Cell Line, Tumor; Dronabinol; Humans; Mitochondria; Mitochondrial Disea	2016
Parkinson Disease and Pioglitazone: Could Traumatic Brain Injury Catch a Lift? World neurosurgery, 2016, Volume: 95 Topics: Disease Models, Animal; Humans; Hypoglycemic Agents; Parkinson Disease; Pioglitazone; Thiazolidinedi	2016
Mining relational paths in integrated biomedical data. PloS one, 2011, Volume: 6, Issue:12 Topics: Algorithms; Computers; Data Collection; Data Mining; Databases, Factual; Humans; Hypoglycemic Agents	2011

pioglitazone and Idiopathic Parkinson Disease